The effectiveness of non-clinical drug safety predictions is enhanced by the adoption of three-dimensional (3D) cellular models. 3D bioprinting enables the generation of complex models with spatial ...

Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...